|
|
|
|
| 專題 |
最後回覆 |
暱稱 |
內容 |
| 長江生命科技集團有限公司 |
2020-06-26T09:25 |
財經茄呢啡 |
長江生命科技（0775）全資附屬公司Polynoma公布，其進行研究的黑色素瘤候選疫苗seviprotimut-L獲得美國食品及藥物管理局批准快速通道資格認定申請，目標為促進治療嚴重或危及生命情況的藥物開發，加快審查，股價曾單日飆升接近兩成。 |
|
|
|
|
We've noticed you're using an ad blocker
We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.
To continue using 88iv.com, please allow this domain on your ad blocker.
We are thanksful for your decisive action.
This notice will be shown again every hour.
Close This Window